Ironwood Pharmaceuticals
Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.
The company discovered, developed and is commercializing linaclotide, the US branded prescription market leader in the IBS-C/CIC category, and is applying its research and development and commercial capabilities to advance multiple internally-developed and externally-accessed product opportunities.
In May 2023, Ironwood entered into a definitive agreement to acquire VectivBio for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of around $1 billion, net of VectivBio cash and debt. The transaction is expected to close in the second half of 2023.
Latest Ironwood Pharmaceuticals News & Features
7 June 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze